An Exploratory Study of Dapagliflozin for the Attenuation of Albuminuria in Patients with Heart Failure and Type 2 Diabetes Mellitus (DAPPER)

Background and Aims Sodium-dependent glucose transporter-2 (SGLT-2) inhibitors, which are anti-diabetic drugs, reportedly decrease the incidence of cardiovascular events in high-risk patients with cardiovascular diseases, and thus chronic heart failure (CHF). SGLT-2 inhibitors also decrease albuminu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cardiovascular drugs and therapy 2018-04, Vol.32 (2), p.183-190
Hauptverfasser:	Yoshihara, Fumiki, Imazu, Miki, Hamasaki, Toshimitsu, Anzai, Toshihisa, Yasuda, Satoshi, Ito, Shin, Yamamoto, Haruko, Hashimura, Kazuhiko, Yasumura, Yoshio, Mori, Kiyoshi, Watanabe, Masataka, Asakura, Masanori, Kitakaze, Masafumi
Format:	Artikel
Sprache:	eng
Schlagworte:	Albuminuria - diagnosis Albuminuria - epidemiology Albuminuria - prevention & control Antidiabetics Benzhydryl Compounds - therapeutic use Beta blockers Biomarkers Cardiology Cardiovascular diseases Creatinine Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Diabetic Nephropathies - diagnosis Diabetic Nephropathies - epidemiology Diabetic Nephropathies - prevention & control Drugs Glucose transporter Glucosides - therapeutic use Health risk assessment Health risks Heart diseases Heart failure Heart Failure - diagnosis Heart Failure - drug therapy Heart Failure - epidemiology Heart Failure - physiopathology Humans Inhibitors Japan - epidemiology Medicine Medicine & Public Health Multicenter Studies as Topic Original Article Patients Randomization Randomized Controlled Trials as Topic Risk Factors Risk groups Sodium Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!